Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

TELA Bio (TELA) EBITDA (2018 - 2026)

TELA Bio has reported EBITDA over the past 8 years, most recently at -$9.0 million for Q4 2025.

  • For Q4 2025, EBITDA rose 2.44% year-over-year to -$9.0 million; the TTM value through Dec 2025 reached -$38.8 million, down 2.61%, while the annual FY2025 figure was -$38.8 million, 2.61% down from the prior year.
  • EBITDA for Q4 2025 was -$9.0 million at TELA Bio, down from -$8.6 million in the prior quarter.
  • Over five years, EBITDA peaked at -$5.7 million in Q1 2024 and troughed at -$12.9 million in Q4 2023.
  • A 5-year average of -$9.6 million and a median of -$9.7 million in 2022 define the central range for EBITDA.
  • Biggest five-year swings in EBITDA: skyrocketed 53.1% in 2024 and later tumbled 99.17% in 2025.
  • Year by year, EBITDA stood at -$7.7 million in 2021, then decreased by 23.32% to -$9.4 million in 2022, then crashed by 37.03% to -$12.9 million in 2023, then grew by 28.35% to -$9.3 million in 2024, then increased by 2.44% to -$9.0 million in 2025.
  • Business Quant data shows EBITDA for TELA at -$9.0 million in Q4 2025, -$8.6 million in Q3 2025, and -$9.9 million in Q2 2025.